Ki67 measured after neoadjuvant chemotherapy for primary breast cancer

Clinical Cancer Research

Volumn 19, Issue 16, 2013, Pages 4521-4531

  Von Minckwitz, Gunter ^a,b   Schmitt, Wolfgang D ^e   Loibl, Sibylle ^a,d   Müller, Berit M ^e   Blohmer, Jens U ^f   Sinn, Bruno V ^e   Eidtmann, Holger ^g   Eiermann, Wolfgang ^h   Gerber, Bernd ⁱ   Tesch, Hans ^c   Hilfrich, Jorn ^j   Huober, Jens ^k   Fehm, Tanja ^l   Barinoff, Jana ^m   Rüdiger, Thomas ⁿ   Erbstoesser, Erhard ^o   Fasching, Peter A ^p   Karn, Thomas ^b   Müller, Volkmar ^q   Jackisch, Christian ^d   Denkert, Carsten ^e   more..

^a C/o GBG Forschungs GmbH ^*  (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Bethanien Krankenhaus Frankfurt   (Germany)

^d Klinikum Offenbach   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f MARTIN LUTHER KRANKENHAUS   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h Frauenklinik vom Roten Kreuz   (Germany)

ⁱ ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^j Henriettenstift Frauenklinik   (Germany)

^k UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^l UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^m Klinikum Essen Mitte   (Germany)

ⁿ STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^o AMEOS Klinikum St Salvator Institut für Pathologie   (Germany)

^p UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^q UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; KI 67 ANTIGEN; NAVELBINE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CONTROLLED STUDY; DEATH; DISEASE FREE SURVIVAL; HIGH RISK PATIENT; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84882945411     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3628     Document Type: Article

References (35)

1. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2011; 19:1508-16
2. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-804.
3. von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. In press 2013.
4. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008;100:552-62.
5. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin- cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008;100: 542-51.
6. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2012;11:174-83.
7. DeCensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, el al. Prognostic significance of Ki67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol 2011;22:582-7.
8. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
9. Lehr HA, Hansen DA, Kussick S, Li M, Hwang H, Krummenauer F, et al. : Assessment of proliferative activity in breast cancer: MIB-1 mmunohistochemistry versus mitotic figure count. Hum Pathol 1999;30:1314-20.
10. Thor AD, Liu S, Moore DH 2nd, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast. J Clin Oncol 1999;17:470-7.
11. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, et al. Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients. Br J Cancer 2007;96:1504-13.
12. Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, et al. Ki67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2011;132: 895-915.
13. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosisand proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-52.
14. Archer CD, Parton M, Smith IE, Ellis PA, Salter J, Ashley S, et al. Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 2003;89:1035-41.
15. von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, et al. Clinical response after two cycles compared to HER2, Ki67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 2008;10:R30.
16. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011;11:486.
17. Miglietta L, Vanella P, Canobbio L, Naso C, Cerisola N, Meszaros P, et al. Prognostic value of estrogen receptor and Ki67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Oncology 2010;79: 255-61.
18. Kumaki N, Umemura S, Tang X, Saito Y, Suzuki Y, Tokuda Y. Alteration of immunohistochemical biomarkers between pre-and post-chemotherapy: hormone receptors, HER2 and Ki67. Breast Cancer 2011;18: 98-102.
19. Tanei T, Shimomura A, Shimazu K, Nakayama T, Kim SJ, Iwamoto T, et al. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 2011;37:155-61.
20. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009;116:53-68.
21. von Minckwitz G, Blohmer JU, Raab G, Lohr A, Gerber B, Heinrich G, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005;16:56-63.
22. Costa SD, Loibl S, Kaufmann M, Zahm DM, Hilfrich J, Huober J, et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol 2010;28:83-91.
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics subcommittee of the NCI-EORTC working group on cancer diagnostics. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-72.
24. Denkert C, Loibl S, Muller BM, Eidtmann H, Eiermann W, Gerber B, et al. Pretherapeutic Ki67 as a predictive and prognostic marker in breast bancer-significance across a wide range of cutpoints. Cancer Res 2012;72 Suppl 24:102s.
25. Remmele W, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 1993;189:862-6.
26. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007;25: 2127-32.
27. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010;124: 133-40.
28. Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 2000;19:2595-609.
29. Chuah BY, Putti T, Salto-Tellez M, Charlton A, Lau P, Buhari SA, et al. Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy. Ann Oncol 2011;22:1748-54.
30. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005;23:7265-77.
31. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380-8.
32. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACO-SOG Z1031. J Clin Oncol 2011;29:2342-9.
33. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011;103:1656-64.
34. Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast-and Gynecopathologists. PLoS ONE 2012;7:e37379.
35. Klauschen F, Wienert S, Blohmer J-U, Mueller BM, Eiermann W, Gerber B, et al. Automated computational Ki67 scoring in the Gepar-Trio breast cancer study cohort. Cancer Res 2012;72 Suppl 24:33s.